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Abstract
© 2017 Kovac, Litvin, Aliev, Zakirova, Rutland, Kiyasov and Rizvanov. In this clinical study, for
the first time we used the direct gene therapy to restore severe injuries of the suspensory
ligament branch and superficial digital flexor tendon in horses (Equus caballus). We injected the
plasmid DNA encoding two therapeutic species-specific growth factors:  vascular endothelial
growth factor 164 and fibroblast growth factor 2 at the site of injury in the suspensory ligament
branch and tendon. Treatment effects were evaluated with the use of clinical observation and
ultrasound imaging during a period of a few months. We showed that gene therapy used within
a period of 2-3 months after the injury resulted in the complete recovery of functions and full
restoration of the severely damaged suspensory ligament and superficial digital flexor tendon.
http://dx.doi.org/10.3389/fvets.2017.00168
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